Optimal infection prophylaxis strategy for relapsed/refractory multiple myeloma patients undergoing elranatamab therapy (OPTIMUS-EL)

Prevymis (letermovir) - Merck (MSD)

Elrexfio (elranatamab-bcmm) - Pfizer

Ja Min Byun 1; Dong Hyun Kim 1; Youngil Koh 1; Chang-Ki Min 2; Kihyun Kim 3; Hee Jeong Cho 4; Ji Yun Lee 5

Dec 5, 2025